ClinConnect ClinConnect Logo
Search / Trial NCT00792727

HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain

Launched by HISAMITSU PHARMACEUTICAL CO., INC. · Nov 17, 2008

Trial Information

Current as of May 24, 2025

Completed

Keywords

Pain Knee Arthritis Knee Pain

ClinConnect Summary

The objective of this study is to demonstrate the short-term multiple dose efficacy and safety of HKT-500 in subjects with pain caused by mild to moderate osteoarthritis of the knee. The goal of the study is to gather additional information about the analgesic efficacy and safety of repeated, 24-hour applications of 2 HKT-500 patches per knee for a total of 28 days in subjects with pain caused by mild to moderate osteoarthritis of the knee.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • man or woman ≥45 years of age.
  • clinical diagnosis of unilateral or bilateral OA of the knee
  • taking an NSAID or acetaminophen on a regular basis and has a history of knee pain amelioration with NSAID or acetaminophen use.
  • mild to moderate OA of the knee at the screening visit
  • subject exhibits an arthritis "flare" in the target knee within 7 days day of withdrawing from a NSAID or acetaminophen.
  • subject understands that treatment will be administered on an inpatient basis.
  • subject is capable of understanding and complying with the protocol and has signed the informed consent document.
  • Exclusion Criteria:
  • subject is a woman of childbearing potential who has a positive urine pregnancy test, is lactating, or who is not surgically sterile
  • subject has symptoms that are attributable to primary inflammatory diseases of the joint
  • subject has unstable knees including a history of the knee catching or giving way or physical examination evidence of instability
  • subject has arthropathies that occur in conjunction with systemic diseases
  • subject has a chronic pain condition
  • subject is grossly obese
  • subject has a history of knee surgery within the past 12 months or arthroscopy within the past 6 months.
  • subject has a history of osteotomies.
  • subject is not willing to discontinue the use of NSAIDs, acetaminophen or other prohibited treatments
  • subject used opioids for OA pain within 1 month

About Hisamitsu Pharmaceutical Co., Inc.

Hisamitsu Pharmaceutical Co., Inc. is a leading global pharmaceutical company based in Japan, renowned for its innovative research and development in transdermal drug delivery systems and topical therapeutic products. Established in 1847, Hisamitsu is committed to improving patient outcomes through the development of effective and safe medications for various medical conditions, including pain management and dermatological disorders. The company prioritizes clinical trials to advance its product pipeline and ensure the highest standards of efficacy and safety, aligning with its mission to enhance the quality of life for patients worldwide.

Locations

Omaha, Nebraska, United States

Zanesville, Ohio, United States

Denver, Colorado, United States

Delray Beach, Florida, United States

San Antonio, Texas, United States

Newport News, Virginia, United States

Birmingham, Alabama, United States

Chandler, Arizona, United States

Peoria, Arizona, United States

San Diego, California, United States

Colorado Springs, Colorado, United States

Daytona Beach, Florida, United States

Fort Myers, Florida, United States

Pembroke Pines, Florida, United States

Evansville, Indiana, United States

Crestview Hills, Kentucky, United States

Fall River, Massachusetts, United States

Las Vegas, Nevada, United States

Reno, Nevada, United States

Albuquerque, New Mexico, United States

Greensboro, North Carolina, United States

Bismark, North Dakota, United States

Cincinnati, Ohio, United States

Columbus, Ohio, United States

Mogadore, Ohio, United States

Oklahoma City, Oklahoma, United States

Tulsa, Oklahoma, United States

Warwick, Rhode Island, United States

Anderson, South Carolina, United States

Austin, Texas, United States

Salt Lake City, Utah, United States

Arlington, Virginia, United States

Charlottesville, Virginia, United States

Yakima, Washington, United States

Patients applied

0 patients applied

Trial Officials

Mr. Kenichi Furuta

Study Director

Hisamitsu Pharmaceutical Co., Inc.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials